We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Learn more about whether Recursion Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ ...

Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire ...

Bay Area life sciences conference will cover the factors behind stabilizing supply and demand for lab space, biotech growth, ...

After raising an impressive 1.2 billion euros in 2024, European venture capital firm Sofinnova Partners is topping up its ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

The phase 3 MINT trial evaluated the efficacy and safety of the drug in both muscle-specific kinase autoantibody ...

This article compares the popular SCHX and SCHX exchange-traded funds and explains the best funds to invest in this year ...

Sofinnova Partners ("Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Biovelocita II. The fund has ...

In the latest trading session, Amgen (AMGN) closed at $317.17, marking a +1.1% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.64%. Meanwhile, the Dow experienced a rise ...